Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vorasidenib versus placebo in residual or recurrent IDH-mutant grade 2 glioma
jRCT2061220059Phase 3Active, not recruiting
- Sponsor
- Servier
- Start
- Dec 2022
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial in glioma comparing Vorasidenib with Matching Placebo (2 arms). Primary endpoint: Progression-free survival. Started Dec 2022; status: active, not recruiting.
02
Drugs
vorasidenib
03
Conditions
glioma
Beyond the preview
Go deeper on jRCT2061220059.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2061220059.